“
“Objective To assess sedative and cardiopulmonary effects of premedication with a medetomidine-buprenorphine or acepromazine-buprenorphine combination in dogs anesthetized with propofol and isoflurane.
Design Randomized controlled clinical trial.
Animals-90 dogs undergoing routine surgical and diagnostic procedures.
Procedures Dogs were randomly assigned to 1 of 3 premedication groups: group 1 (acepromazine, 0.03 mg/kg [0.014 mg/lb], IM; buprenorphine,
0.02 mg/kg [0.009 mg/lb[, IM), 2 (medetomidine, 5 mu g/kg [2.3 mu g/lb], IM; buprenorphine, 0.02 mg/kg, IM), or 3 (medetomidine, 10 mu g/kg [4.5 mu g/lb], IM; buprenorphine, 0.02 mg/kg, IM). Anesthesia was induced with propofol and maintained with isoflurane in oxygen. Simple descriptive scores for sedation were assigned 15 minutes BTSA1 Selleckchem Navitoclax (groups 2 and 31 and 30 minutes (group 1) after premedication administration. Basic cardiopulmonary data were recorded throughout the anesthetic period. Times to recovery from anesthesia were recorded.
Results Sedation scores did not differ significantly among groups. Mean and diastolic blood pressures were significantly lower and heart rate was significantly higher in group 1 than in the other
groups. Mean end-tidal partial pressure of CO2 was significantly lower and respiratory rate was significantly higher in group 1 than in the other groups. There were no significant differences in anesthetic recovery times between groups.
Conclusions and Clinical Relevance Results suggested that either acepromazine or medetomidine could be used in combination
with buprenorphine for premedication of dogs anesthetized with propofol and isoflurane for routine surgical and diagnostic procedures. Arterial blood pressure was better maintained with the medetomidine-buprenorphine combinations, but tissue perfusion was not investigated. (J Am Vet Med Assoc 2010;237:1431-1437)”
“The objective of the present study was to prepare ceramic nanoparticles of a poorly aqueous soluble drug (piroxicam) to explore the relationship between particle size and dissolution profile. Ceramic nanoparticles were prepared by self-assembling of hydroxyapatite using colloidal SHP099 Others inhibitor precipitation technique, with the aid of refluxing. Then the nanoparticles were coated with trehalose (polyhydroxyl oligomer) and subsequently piroxicam was allowed to adsorb. These ceramic nanoparticles were characterized for the shape, size, size distribution, yield, drug loading and release profile. The SEM analysis indicated spherical particles with a particle size median of 238 nm. The percent yield of ceramic nanoparticles was 66.7 %. The dissolution profile of piroxicam aquasomes was obtained in 0.1 mol/L hydrochloric acid solution.